Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics announced the publication of a study comparing its Saphyr system with traditional cytogenomics methods for analyzing Myelodysplastic Syndromes (MDS). The study showed that optical genome mapping (OGM) detected all actionable variants and additional relevant aberrations missed by standard methodologies, enhancing clinical decision-making. Saphyr reduces the diagnostic process from weeks to just 4 days, potentially accelerating patient treatment. With OGM's high-throughput capabilities, it may streamline chromosomal analysis for MDS and other cancers.
Bionano Genomics (NASDAQ: BNGO) announced findings from the COVID-19 Host Genome Structural Variant Consortium, highlighting the Saphyr system's effectiveness in identifying structural variants (SVs) in severe COVID-19 patients. Key findings indicate that SVs affecting immunity and viral replication pathways are linked to disease severity, particularly in the interferon response pathway. The consortium aims to analyze 1,000 genomes to enhance understanding of COVID-19 susceptibility, with significant collaborations from renowned institutions worldwide.
Bionano Genomics (BNGO) highlighted groundbreaking advancements in optical genome mapping (OGM) with its Saphyr system during a recent symposium. Notable achievements include the ability to assess large genomic repeat expansions previously deemed unmeasurable. Clinical validations presented suggest that Saphyr enhances diagnostic accuracy, exemplified by a 25% increase in diagnostic yield for undiagnosed genetic diseases. The University of Iowa and KU Leuven also developed cost-effective assays for Facioscapulohumeral Muscular Dystrophy (FSHD) testing, advancing clinical diagnostics in pediatric genetic disorders.
Bionano Genomics (BNGO) announced positive preliminary findings on its Saphyr system, presented at the Next-Generation Cytogenomics Symposium. The system demonstrated superior performance over the Oncoscan array for detecting structural and copy number variations in solid tumors. Six studies highlighted Saphyr's capability to unveil complex genomic changes in various cancers, including brain and breast cancers, revealing new therapeutic targets. The studies showed that Saphyr achieved 100% concordance with existing testing methods while offering faster, cost-effective solutions for clinical applications.
Bionano Genomics (Nasdaq: BNGO) announced its compliance with Nasdaq's minimum bid price requirement. The company received a notification confirming that its common stock closing bid price has been at $1.00 or greater for the last 10 consecutive business days, from December 29, 2020, to January 12, 2021. This achievement fulfills the Listing Rule 5550(a)(2) criteria, and the matter is now considered closed.
Bionano Genomics (BNGO) announced successful results from Saphyr users at the Next-Generation Cytogenomics Symposium, demonstrating its efficacy in analyzing hematological malignancies. Saphyr identifies actionable genetic variants better than traditional cytogenetic methods, such as karyotyping and FISH, while offering faster results at a lower cost. KU Leuven Hospitals is adopting the Saphyr-based assay for routine Acute Lymphoblastic Leukemia diagnostics, showcasing its potential to streamline clinical workflows and improve diagnostic accuracy.
Bionano Genomics, Inc. (BNGO) has successfully closed its underwritten public offering of 33,368,851 shares at $3.05 per share, raising approximately $101.8 million in gross proceeds. This offering includes the full exercise of the underwriters' option to purchase 4,352,458 additional shares. The shares were offered under a previously filed shelf registration statement and are designed to support Bionano's genome analysis services and products.
Bionano Genomics presented findings at the Next-Generation Cytogenomics Symposium, showcasing the Saphyr system's effectiveness in genetic testing. Notable achievements include a 100% concordance in prenatal testing between Saphyr and standard methods like karyotyping, leading to quicker and cost-effective results. Studies across the US, Europe, and China demonstrated Saphyr's reproducibility and ability to resolve rare genetic diseases. Experts from various institutions highlighted Saphyr's advantages in uncovering actionable insights, thereby enhancing diagnostic capabilities in genetic disorders.
Bionano Genomics (Nasdaq: BNGO) announced the publication of findings from the COVID-19 Host Genome Structural Variant Consortium. The study utilized the Saphyr System to identify significant structural variants (SVs) linked to immune responses and disease severity in COVID-19 patients. Analysis of 37 ICU patients revealed that 12 died, while 25 recovered. Notably, a duplication of the STK26 gene was associated with severe illness, suggesting its potential as a prognostic biomarker. The findings highlight Saphyr’s capability in revealing critical genetic insights overlooked by traditional methods.
Bionano Genomics (BNGO) announced its 5-day Next-Generation Cytogenomics Symposium starting January 11, featuring 33 presentations from Saphyr users at leading medical institutions. The event will spotlight applications of optical genome mapping (OGM) for analyzing genetic diseases and blood cancers, alongside studies validating clinical assays. Notably, a session will focus on COVID-19 related genome studies. CEO Erik Holmlin emphasized Saphyr's capability to detect structural variants that traditional methods overlook, potentially increasing diagnostic yields.